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Design: Rapid CD4 cell loss represents an HIV phenotype used to
identify causal variants of accelerated disease progression. The
optimal rate and threshold for identifying this extreme phenotype in
recently infected individuals is unclear.
Methods: Using a cohort of patients with known dates of HIV-1
seroconversion (SC), CASCADE (Concerted Action on SeroConver-
sion on AIDS and Death in Europe), we identiﬁed proportions
experiencing nadir CD4 cell levels within 1 year of SC, and assessed
their mean AIDS-free survival time at 10-year follow-up and hazard of
AIDS/death, compared with those whose CD4 remained .500 cells
per cubic millimeter. Follow-up was censored at December 31, 1996
to avoid bias due to combination antiretroviral therapy initiation.
Results: Of 4876 individuals, 2.8%, 7.3%, and 24.9% experienced $1
CD4,100, 200, and 350 cells per cubic millimeter, respectively, within
1 year of SC. Minimum CD4 levels of 30, 166, 231, and 506 cells per
cubic millimeter were experienced during this period by 1%, 5%, 10%,
and 50% of individuals, respectively. Mean (95% conﬁdence interval)
AIDS-free survival at 10 years follow-up was 2.9 (2.3 to 3.6), 5.5 (5.0 to
6.1), 6.7 (6.5 to 7.0), 7.4 (7.2 to 7.6), and 8.1 (7.9 to 8.3), for those
with minimum counts #100, 100–200, 200–350, 350–500, .500
cells per cubic millimeter, respectively. Using counts of .500 cells
per cubic millimeter as reference, the hazard ratios (95% conﬁdence
interval) of AIDS/death were 15.0 (11.9 to 18.9), 3.6 (2.9 to 4.5),
2.1 (1.8 to 2.4), and 1.5 (1.3 to 1.7), respectively. The hazard ratio
increased to 37.5 (26.5 to 53.1) when a minimum CD4 count ,100
was conﬁrmed within 1 year of SC.
Conclusion: At least 1 CD4#100 cells per cubic millimeter within
the ﬁrst year of SC identiﬁes a rare group of individuals at high risk
of disease progression and could form the basis for deﬁning the rapid
progressor phenotype.
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INTRODUCTION
Rapid HIV disease progression is an extreme HIV
phenotype, although there is little consensus on a deﬁnition.
Differences in HIV disease progression can be assessed by
variability in biomarkers related to HIV disease, the 2 most
common of which being CD4 and HIV-RNA. Variability in
HIV-RNA, speciﬁcally low-circulating HIV-RNA, has
deﬁned those with slow disease progression, termed long-
term nonprogressor or elite controller phenotypes, which are
of particular importance to vaccine studies.1–10 Rapid progres-
sion, however, is equally important as it also contributes to
our understanding of early risk factors of disease progression.
This may in turn help optimize the frequency of clinical mon-
itoring and antiretroviral therapy initiation.
In addition to the well-documented relationship between
slow disease progression and low HIV-RNA, there is also known
variation in CD4 levels at or shortly after seroconversion (SC). A
number of studies to date have deﬁned rapid progression based
on various levels of immunosuppression,11–21 but it is not yet
clear if this variability in CD4, 1 early measure or consecutive
low CD4 measurements do, indeed, constitute rapid progres-
sion and how this rare phenotype should be deﬁned.
The CASCADE (Concerted Action on SeroConversion
on AIDS and Death in Europe) Collaboration, of HIV-
positive individuals followed-up since HIV SC offers a unique
opportunity to evaluate HIV rapid progression. Using data
from CASCADE, we aim to document low CD4 near SC and
examine HIV rapid disease progression. This work provides
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the basis for choosing a deﬁnition appropriate to the
objectives of future research on this extreme phenotype.
METHODS
Study Population
We used data from the CASCADE 2011 data release
in EuroCoord (www.EuroCoord.net), which consists of
25,629 seroconverters from 28 cohorts across Europe, Can-
ada, Australia, and sub-Saharan Africa.22 Date of HIV SC
were estimated by various methods, most commonly as the
midpoint between the last documented HIV-negative and the
ﬁrst positive HIV antibody test dates with an interval of ,3
years between the 2 test dates (85%). For the remainder, date
of SC was estimated through laboratory evidence of SC
(polymerase chain reaction positivity in the absence of
HIV antibodies or antigen positivity with fewer than 4 bands
on Western blot) (13%), or as the date of a SC illness (2%)
with both an earlier documented negative and a later positive
HIV test not more than 3 years apart. All cohorts contribut-
ing data to CASCADE received approval from their individ-
ual ethics review boards.
Rapid Progression
Because of the inconsistency of deﬁnitions described in
the literature,11–21 with nadir CD4 cell counts ranging between
200 and 500 cells per cubic millimeter and follow-up ranging
between 6 months and 8 years, we sought to identify those at
highest risk of disease progression by severity of immuno-
suppression in early infection. We evaluated the frequency of
low CD4 counts during the ﬁrst year after SC and estimated
the mean survival time at 10 years of follow-up and hazard of
AIDS/death by nadir CD4 levels compared with individuals
whose CD4 measurements remained above such levels during
that period.
Statistical Methods
For all estimates, we considered only data from
individuals who met the requirements for length of follow-
up and minimum number of CD4 measurements. More
speciﬁcally, only individuals with at least 1 CD4 count
measured within the ﬁrst year of SC could contribute
information to assessing the risk associated with experiencing
any speciﬁc nadir CD4 cell count within 1 year.
To provide estimates of the prevalence of low CD4
near SC, we calculated proportions experiencing various
nadir CD4 levels within the ﬁrst year of SC by mode of
HIV transmission and age categories and plotted the
cumulative proportion of individuals experiencing different
nadir CD4 levels.
We used Cox proportional hazards models to estimate
the relative hazard of AIDS/death among eligible individ-
uals. As the nonproportionality assumption was not met in
3 of the 4 models, we used log-rank P values.23 We esti-
mated restricted mean AIDS-free survival times (the area
under the length of AIDS-free survival curves) at 10 years
of follow-up using clinically relevant CD4 categories
(,100, 100–200, 200–350, 350–500, and .500 cells/
mm3) using pseudovalues, as described previously.23,24
The follow-up time of 10 years was chosen as this is the
median time to AIDS in the pre–combination antiretroviral
therapy (cART) era for individuals infected between 25 and
35 years of age and was close to the last observed event
time.25 We also used fractional polynomials to explore the
relationship of nadir CD4 measurements to the hazard of
AIDS/death and restricted mean AIDS-free survival.26 For
all models, we adjusted for the following potential con-
founders: sex, mode of HIV transmission, age at SC, and
year at SC. Age and year of SC were modeled using
restricted cubic splines with 3 knots.27 For all analyses,
follow-up was censored at the earliest of AIDS or death date
or on December 31, 1996 to avoid bias because of treatment
initiation. AIDS was deﬁned using the European case deﬁnition,
which excludes CD4 ,200 cells per cubic millimeter.28
In sensitivity analyses, we investigated the proportions
experiencing nadir CD4 measurements within 6 months of SC
TABLE 1. Baseline Characteristics for (A) 4876 Individuals
With $1 CD4 Cell Measurement(s) Within 1 year of SC
Included in Analysis and (B) 6084 Individuals Not Included in
the Analysis but Seroconverting in the Pre-cART Era Using the
CASCADE Data Set
A B
Risk category, n (%)
MSM 2564 (53) 2612 (43)
MSW 1026 (21) 1741 (29)
IDU 1085 (22) 1243 (21)
Other/unknown 201 (4) 486 (7)
Sex, n (%)
Male 3798 (78) 4638 (76)
Female 1078 (22) 1446 (24)
SC year
Median (IQR), yrs 1992 (1989–1994) 1991 (1988–1994)
SC age
Median (IQR), yrs 29 (25–35) 28 (24–33)
,20, n (%) 239 (5) 454 (7)
$20–30, n (%) 2481 (51) 3377 (56)
$30–40, n (%) 1479 (30) 1613 (27)
$40, n (%) 677 (14) 640 (11)
Geographical origin, n (%)
Europe 3652 (78) 4765 (75)
Africa 117 (3) 170 (2)
Americas 50 (1) 77 (1)
Unknown/Other 1057 (18) 1072 (22)
Time from SC to nadir CD4:
median (IQR), mo
7.4 (4.5–9.8) —
Time from SC to ﬁrst CD4:
median (IQR), mo
5.2 (3.0–7.9) —
Number of CD4 counts:
median (IQR)
2 (1–2) —
Follow-up time: median (IQR) 3.8 (1.9–6.1) —
IDU, injection drug users; MSM, men who have sex with men; MSW, heterosexual
contact.
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and the hazard of AIDS/death observed by these minimum
levels. We also investigated if conﬁrmed CD4 measurements
(ie, 2 counts) had an impact on the proportion, mean AIDS-
free survival times, and hazard of AIDS/death within 6
months and 1 year of SC. Additionally, as the individuals
in CASCADE are geographically diverse, we stratiﬁed all




Of 25,629 seroconverters, 20,753 were excluded for
following reasons: 14,669 seroconverted after 1997, 6074 had
no CD4 measurements within the ﬁrst year of SC, 6 had an
unknown AIDS date and 4 were ,15 years of age at SC. Of
the remaining 4876 individuals who were studied, 53% were
men infected through sex between men (men who have sex
with men), 21% through heterosexual contact, 22% through
injection drug use, and the remainder were hemophiliacs or
with unknown risk categories. The majority (78%) were male
seroconverting at a median [interquartile range [IQR]) 29
(25–35) years old between 1982 and 1996. Median (IQR)
time from SC to the lowest CD4 was 7.4 (4.5–9.8) months.
Geographical origin was predominately European (78%) with
few individuals from Africa (3%) and the Americas (1%)
(Table 1). HIV subtype was missing for .80% of individuals
in this analysis, but of those with known subtype, the data
comprised mainly subtype B (.90%).
Baseline characteristics of the 6084 individuals serocon-
verting in the pre-cART era excluded from this analysis and
the sensitivity analysis were similar to the 4876 individuals
included in this analysis (Table 1) (see Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A542).
CD4 Near SC
Median (IQR) initial CD4 count during the ﬁrst year of
SC was 550 (384–726). A total of 138 (2.8%), 356 (7.3%),
and 1213 (24.9%) experienced at least 1 CD4 below 100,
200, and 350 cells per cubic millimeter, respectively, in the
ﬁrst year of SC (Fig. 1, Table 2). About 1%, 5%, 10%, and
50% of individuals experienced at least 1 CD4 ,30, 166,
231, and 506 cells per cubic millimeter, respectively, within
the ﬁrst year of SC (Table 2). Higher CD4 cell levels were
experienced by younger individuals and those infected
through injection drug use (Table 2).
In sensitivity analyses, data were available from 2641,
2825, and 894 individuals with a conﬁrmed CD4 within 1
year of SC, at least 1 CD4 within 6 months, and a conﬁrmed
CD4 within 6 months, respectively. Nadir CD4 percentiles
remained qualitatively similar to those obtained from the
main analysis (see Table S2, Supplemental Digital Content,
http://links.lww.com/QAI/A542).
FIGURE 1. Cumulative proportions of nadir CD4 cell count (left hand panel), relative risk of AIDS/death compared with in-
dividuals whose CD4 counts remained at 500 cells per cubic millimeter (center panel), and mean AIDS-free survival time at 10
years follow-up (right hand panel) for individuals in CASCADE experiencing specific nadir levels within 1 year of SC during that
period: all individuals seroconverted in the pre-cART era.
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Predicted Mean Survival Time at
10-Year Follow-Up
The AIDS-free survival expectancy at 10 years follow-up
signiﬁcantly increased as nadir CD4 count measured within the
ﬁrst year of SC increased (Fig. 1, Table 3). Compared with
individuals experiencing nadir CD4 counts ,100 cells per
cubic millimeter within the ﬁrst year of SC, those with nadir
CD4 of 100–200, 200–350, 350–500, and .500 have an
increased AIDS-free survival expectancy of 2.6 (1.7–3.4), 3.8
(3.1–4.45), 4.5 (3.8–5.2), and 5.2 (4.5–5.5) years, respectively,
during the ﬁrst 10 years of HIV infection.
In a sensitivity analysis, the AIDS-free survival expec-
tancy was qualitatively similar to results in the main analysis,
increasing as nadir CD4 count and conﬁrmed minimum CD4
measurements increased within 1 year and the 6 months of SC
(Table 3). Predicted mean survival at 10 years follow-up was
qualitatively similar when stratifying by geographical origin
(data not shown).
Risk of AIDS/Death by Nadir CD4
The risk of AIDS/death increased as nadir CD4 count
measured in the ﬁrst year decreased. For individuals experi-
encing at least 1 count ,100 cells per cubic millimeter, there
was a 15-fold increased risk of AIDS/death compared with
those whose nadir CD4 count remained .500 cells per cubic
millimeter. Hazard of AIDS/death was signiﬁcantly higher
for those with nadir counts ,500 cells per cubic millimeter,
(Fig. 1, Table 3).
In sensitivity analyses, the risk of AIDS/death was
qualitatively similar to results in main analyses. As
expected, however, the risk was greatly elevated for those
experiencing conﬁrmed counts, namely; hazard ratio (95%
conﬁdence interval) 15.0 (11.9 to 18.9) vs. 37.5 (26.5 to
53.1) for CD4 #100 cells per cubic millimeter and 3.6 (2.9
to 4.5) vs. 6.3 (4.5 to 8.8) for CD4 100–200 cells per cubic
millimeter comparing a single minimum CD4 count with
a conﬁrmed CD4 count within 1 year of SC. This same
pattern was observed when comparing nadir CD4 with
a conﬁrmed minimum CD4 count within 6 months of SC,
(Table 3). There was a similar trend of higher risk of AIDS/
death for lower CD4 cell counts when stratifying by geo-
graphical origin (data not shown).
DISCUSSION
Individuals experiencing 1 or more CD4 cell count #100
cells per cubic millimeter within the ﬁrst year of SC provide
a rare group (2.8%) of HIV-positive individuals at the highest
risk of disease progression with remarkably short mean
AIDS-free survival of 2.9 years. These results suggest that
CD4 monitoring close to SC may play an important role in
identifying those at highest risk of progression. In addition to
this, individuals with at least 1 CD4 cell count#500 cells per
cubic millimeter are at an increased risk of AIDS/death com-
pared with individuals whose CD4 remain above 500 cells
per cubic millimeter.
We have shown that low CD4 cell counts ,100 cells
per cubic millimeter near SC is rare, but low CD4 near SC can
TABLE 2. Minimum CD4 Percentiles Within 1 year of SC by
HIV Risk Group and Age Categories in the Pre-cART Era
Using the CASCADE Data Set
,20 ‡20–30 ‡30–40 ‡40 Overall
1%
MSM 165 49 27 30 35
IDU 244 53 22 185 40
MSW 154 19 27 23 27
OTH — 65 0 24 19
Overall 156 49 24 24 30
5%
MSM 220 168 156 124 161
IDU 318 210 141 240 200
MSW 257 168 135 95 156
OTH — 136 48 64 112
Overall 257 180 148 118 166
10%
MSM 270 237 223 213 224
IDU 338 269 220 339 265
MSW 300 255 220 190 225
OTH — 240 182 192 200
Overall 307 250 220 204 231
25%
MSM 342 352 340 315 340
IDU 439 425 343 364 405
MSW 440 370 350 268 350
OTH — 404 289 328 318
Overall 389 378 340 311 352
50%
MSM 450 500 487.5 441 484.5
IDU 597 600 510 419.5 583
MSW 560 519 491 430 501.5
OTH — 546 500 474 502
Overall 530 535 491 440 506
75%
MSM 638 676 650 614 654
IDU 778 825 766 725 815
MSW 840 732 722.5 603 751
OTH 667 726 800 612 721
Overall 717 736 680 612 705.5
90%
MSM — 875 842 830 856
IDU 947 1063 1045 1029 1057
MSW 997 979 970 824 950
OTH 842.5 977 1154 800 942
Overall 947 966 907 830 933
100%
MSM 1250 1704 1875 1584 1875
IDU 1984 2105 1744 2420 2420
MSW 1453 2231 2156 1625 2231
OTH — 1704 2068 1357 2068
Overall 1984 2231 2156 2420 2420
IDU, injection drug users; MSM, men who have sex with men; MSW,
heterosexual contact; OTH, hemophiliacs or unknown.
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have other research implications. Our deﬁnition can be useful
for researching extreme phenotypes, particularly for genetic
studies aiming to identify rare causal variants by looking at
extreme ends of HIV disease progression.29,30 In addition to
genetic implications, low CD4 near SC can have impact on
HIV incidence measurements. HIV incidence measures such
as The Recent Incidence Testing Algorithm aim to identify
individuals infected within 4–6 months of sampling but
exclude individuals who have AIDS, on ART or are identiﬁed
with low CD4 as these individuals have been shown to be
misclassiﬁed as recently infected.31 Our study suggests that
up to 5% of the HIV-positive population tested in the ﬁrst 6
months of SC will have a CD4 below 200 and thus would be
misclassiﬁed as longstanding infection according to The
Recent Incidence Testing Algorithm. These results suggest
the need for an incidence estimate correction factor to account
for low CD4 cell counts near SC.
Individuals experiencing conﬁrmed low CD4 meas-
urements ,200 cells per cubic millimeter had more than
a 2-fold increased risk of AIDS/death compared with mini-
mum CD4 measurement alone. Although this may suggest
that a conﬁrmatory CD4 has a higher prognostic value of
disease progression than a single CD4 alone, it is unusual
for individuals to have a conﬁrmed CD4 so close to SC,
shown by our reduced numbers for this population. We were
able to analyze repeated low CD4 measurements because
these data were restricted to the pre-cART era; however, it
is unlikely that in the cART era naive low conﬁrmed CD4
measurements would be available, as all individuals with 1
CD4 ,200 cells per cubic millimeter are recommended to
be on treatment.
Subtype was missing for .80% of individuals in this
analysis, and comprised mainly subtype B (90%), which com-
pared with other HIV subtypes, has previously been shown to
have different rates of CD4 cell levels near SC and CD4 rates
of decline suggesting these results may not be generalizable to
other HIV subtypes.32 We stratiﬁed the analysis by geograph-
ical origin and the same trend of higher risk of disease pro-
gression with lower CD4 cell counts was observed, suggesting
these results are generalizable in different global epidemics.
Our study has several strengths. First, the availabil-
ity of SC estimation is essential to identifying individuals
with rapid disease progression. Without laboratory evi-
dence of SC, individuals entering care with low
CD4 would be termed late presenters instead of rapid
progressors.33 Second, the availability of data in an era
when ART was not used early in the course of disease
allowed us to assess rapid progression without the inter-
action of ART on disease progression. In the cART era,
individuals with CD4 ,350 cells per cubic millimeter
would be on cART and the impact of low CD4 ,100 cells
per cubic millimeter near SC would not be fully under-
stood. Finally, the large sample size of our cohort allows
us to compare between different possible combinations of
this rare phenotype.
Our study has limitations. SC illness and HIV test
intervals ,31 days have been shown to be associated with
faster disease progression,34,35 suggesting our proportion
and risk estimates could be overinﬂated because of the
increased likelihood of individuals seeking care when
experiencing SC illness, although the midpoint method of
estimating SC was used for 85% of seroconverters. We
were unable to test if rapid progressors are more likely to
report SC illness, as this is unknown in .70% of the CAS-
CADE data set. However, among 1481 individuals in our
study with known SC illness status, . 50% of individuals
reported of SC illness with CD4 count ,350 cells per
cubic millimeter, where ,50% of individuals reported no
SC illness in those with a CD4 count $350 cells per cubic
millimeter (data not shown). Although our study only
TABLE 3. HR for Time to AIDS/Death by Nadir CD4 Measured Within 1 year of SC Using the CASCADE Data Set
CD4 Value, cells/mm3
Within 6 Months of SC Within 1 Year of SC
N (Fail) HR (95% CI)*
Mean AIDS-Free




#100 58 (37) 12.8 (9.0 to 18.2)‡ 3.1 (2.1 to 4.1) 138 (94) 15.0 (11.9 to 18.9)‡ 2.9 (2.3 to 3.6)
100–200 97 (40) 2.9 (2.1 to 4.1)‡ 5.6 (4.7 to 6.5)§ 218 (91) 3.6 (2.9 to 4.5)‡ 5.5 (5.0 to 6.1)§
200–350 409 (134) 2.3 (1.9 to 2.8)‡ 6.3 (5.9 to 6.6)§ 857 (267) 2.1 (1.8 to 2.4)‡ 6.7 (6.5 to 7.0)§
350–500 607 (180) 1.6 (1.3 to 1.9)‡ 7.0 (6.7 to 7.3)§ 1185 (316) 1.5 (1.3 to 1.7)‡ 7.4 (7.2 to 7.6)§
.500 1654 (359) 1‡ 8.0 (7.8 to 8.1)§ 2478 (501) 1‡ 8.1 (7.9 to 8.3)§
Conﬁrmed CD4
#100 14 (10) 49.3 (23.4 to 104.2) 2.1 (0.4 to 3.7) 64 (51) 37.5 (26.5 to 53.1)‡ 1.8 (1.1 to 2.6)
100–200 33 (17) 7.4 (4.2 to 13.0) 3.6 (2.3 to 5.0) 92 (40) 6.3 (4.5 to 8.8)‡ 4.9 (4.0 to 5.7)§
200–350 118 (36) 2.5 (1.7 to 3.7) 5.6 (4.9 to 6.4)§ 342 (106) 2.4 (1.9 to 3.0)‡ 6.3 (5.9 to 6.7)§
350–500 186 (61) 1.6 (1.2 to 2.3) 6.1 (5.5 to 6.7)§ 577 (171) 1.8 (1.5 to 2.1)‡ 6.8 (6.4 to 7.1)§
.500 543 (130) 1 7.3 (6.9 to 7.7)§ 1566 (344) 1‡ 7.9 (7.7 to 8.1)§
*Adjusted for sex, risk group, SC age, SC year, log-rank test P , 0.001.
†Mean AIDS-free survival at 10 years of follow-up.
‡Cox proportional hazards P , 0.05.
§Statistically greater than #100 cells per cubic millimeter category (P , 0.001).
CI, conﬁdence interval; HR, hazard ratio.
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investigates seroconverters, it has been shown that HIV
progression, in particular CD4 decline, among sero-
converters is similar to that of the general HIV-positive
population suggesting our results are generalizable to the
HIV-positive population.36
In conclusion, individuals with at least 1 CD4 #100
cells per cubic millimeter in the ﬁrst year of SC are a rare and
extreme group who are at a very high risk of rapid disease
progression. Given that the HIV test intervals in this study are
consistent with HIV testing guidelines,37–40 our study allows
clinicians to identify individuals at risk of progression at an
early stage for whom immediate initiation of therapy may be
indicated. This study has also helps to identify an extreme
HIV phenotype that increases power to detect rare variants in
causal viral and host genetics of rapid HIV disease progres-
sion. This may, in turn, lead to targeted treatments for indi-
viduals at the greatest risk of progression. We suggest future
research use at least 1 CD4 #100 cells per cubic millimeter
within 1 year of SC as a deﬁnition for rapid progression.
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